Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-08
2011-03-08
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S144100, C424S178100, C424S179100, C424S184100, C424S192100, C424S193100, C530S387300, C530S388220, C530S324000
Reexamination Certificate
active
07901680
ABSTRACT:
The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4699784 (1987-10-01), Shih et al.
patent: 4818709 (1989-04-01), Primus et al.
patent: 4868109 (1989-09-01), Lansdorp et al.
patent: 5194254 (1993-03-01), Barber et al.
patent: 5478556 (1995-12-01), Elliot et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5571515 (1996-11-01), Scott et al.
patent: 5614610 (1997-03-01), Hellstrom et al.
patent: 5770198 (1998-06-01), Coller et al.
patent: 5798100 (1998-08-01), Hansen
patent: 5874540 (1999-02-01), Hansen et al.
patent: 6132718 (2000-10-01), Hansen
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6306393 (2001-10-01), Goldenberg et al.
patent: 6440416 (2002-08-01), Hansen et al.
patent: 6524854 (2003-02-01), Monia et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 6926893 (2005-08-01), Hansen
patent: 7060506 (2006-06-01), Craig
patent: 7151164 (2006-12-01), Hansen et al.
patent: 7312318 (2007-12-01), Hansen et al.
patent: 7354587 (2008-04-01), Hansen
patent: 7432342 (2008-10-01), Braun et al.
patent: 7521056 (2009-04-01), Chang et al.
patent: 7527787 (2009-05-01), Chang et al.
patent: 7534866 (2009-05-01), Chang et al.
patent: 7541440 (2009-06-01), Goldenberg et al.
patent: 7550143 (2009-06-01), Chang et al.
patent: 7591994 (2009-09-01), Govindan et al.
patent: 7666400 (2010-02-01), Chang et al.
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2003/0228326 (2003-12-01), Palomba et al.
patent: 2003/0232420 (2003-12-01), Braun et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0210475 (2006-09-01), Goldenberg et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: 2006/0228357 (2006-10-01), Chang et al.
patent: 2007/0020259 (2007-01-01), Hansen et al.
patent: 2007/0086942 (2007-04-01), Chang et al.
patent: 2007/0140966 (2007-06-01), Chang et al.
patent: 2008/0166363 (2008-07-01), Govindan et al.
patent: 2008/0187515 (2008-08-01), Hansen et al.
patent: 2009/0060862 (2009-03-01), Chang et al.
patent: 2009/0111143 (2009-04-01), Goldenberg et al.
patent: 2009/0191225 (2009-07-01), Chang et al.
patent: 2009/0202433 (2009-08-01), Chang et al.
patent: 2009/0202487 (2009-08-01), Chang et al.
patent: 2009/0269277 (2009-10-01), Chang et al.
patent: 2010/0189641 (2010-07-01), Chang et al.
patent: 2010/0189689 (2010-07-01), Chang et al.
patent: 0324625 (1989-07-01), None
patent: 0340793 (1995-08-01), None
patent: 0438803 (1997-03-01), None
patent: 0306995 (1997-04-01), None
patent: 91/11465 (1991-08-01), None
patent: 92/15322 (1992-09-01), None
patent: 93/11162 (1993-06-01), None
patent: 94/05329 (1994-03-01), None
patent: 96/04313 (1996-02-01), None
patent: 96/37224 (1996-11-01), None
patent: 96/40941 (1996-12-01), None
patent: 00/68248 (2000-11-01), None
patent: 2006/107617 (2006-10-01), None
patent: 2006/107786 (2006-10-01), None
patent: WO 2006/107786 (2006-10-01), None
patent: WO 2007/046893 (2007-04-01), None
patent: 2007/075270 (2007-07-01), None
patent: 2008/033413 (2008-03-01), None
Chang et al, Clin Cancer Res 13 (18): 5586s-5591s; Sep. 15, 2007.
Fong et al, J Immunology 167: 7150-7156, 2001.
Tedder et al, J Immunol 141(12): 4388-4391, Dec. 1988.
Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.
Alto et al., “Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring” Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.
Backer et al., “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins” Bioconjugate Chem., 2006, 17(4):912-919.
Baillie et al., “Compartmentalisation of phospodiesterases and protein kinase A: opposites attract”, FEBS Letters 2005; 579:3264-3270.
Banky et al., “Dimerization/Docking Domain of the Type Iα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998.
Basu et al., “Structure-Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation”, Bioconjugate Chem. 2006; 17:618-630.
Belardelli et al., “Interferon-alpha in tumor immunity and immunotherapy” Cytokine Growth Factor Rev. 13(2):119-134 (2002).
Belardelli et al., “International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?” Cancer Res. 64:6827-6830 (2004).
Belardelli et al., “The neglected role of type I interferon in the T-cell response: implications for its clinical use” Immunol. Today 17(8):369-72 (1996).
Biron et al., “Natural killer cells in antiviral defense: function and regulation by innate cytokines” Annu. Rev. Immunol. 17:189-220 (1999).
Brunda et al., “Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons” Cancer Res. 44:597-601 (1984).
Burns-Hamuro et al., “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange” Protein Science (2005), 14:2982-2992.
Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991).
Carr et al., “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA” J. Biol. Chem. 276(20):17332-17338 (2001).
Carrero et al., “Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes” J. Exp. Med. 203(4):933-940 (2006).
Chang et al., “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity” Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.
Chmura et al., “Antibodies with infinite affinity” Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).
Colledge et al., “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999).
Corbin et al., “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973).
Dhalluin et al., “Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers” Bioconjugate Chem. 2005;16:504-517.
Dodart et al., “Immunotherapy for Alzheimer's Disease: will vaccination work?” Trends Mol. Med. 9(3):85-87 (2003).
Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Bioconjugate Chem. 2005;16:1291-1298.
Ferrantini et al., “IFN-α1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity” J. Immunol. 153:4604-15 (1994).
Ferrantini et al., “Interferon-α and cancer: M
Chang Chien-Hsing
Goldenberg David M.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
Dock-and-lock (DNL) vaccines for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dock-and-lock (DNL) vaccines for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dock-and-lock (DNL) vaccines for cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666259